We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors.
- Authors
Mullenix, Cristina; Ballman, Madison; Chen, Haobin; Swift, Shannon; McAdams, Meredith J; Tsai, Yo-Ting; Donahue, Renee N; Poretta, Trina; Gupta, Sarthak; Loehrer, Patrick J; Schlom, Jeffrey; Gulley, James L; Rajan, Arun
- Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers. However, activation of the immune system can occasionally cause life-threatening toxicity involving critical organs. Induction of immune-mediated toxicity is a significant concern for patients with thymic epithelial tumors (TETs) due to defects in immune tolerance. An increased risk of skeletal and cardiac muscle inflammation following treatment with ICIs is well recognized in patients with advanced TETs. However, uncommon musculoskeletal and rheumatic complications can also occur. The cases presented in this report highlight the spectrum of presentation of immune-mediated, joint-predominant musculoskeletal adverse events in patients with advanced TETs treated with ICIs, including polymyalgia rheumatica-like illness and inflammatory arthritis.
- Subjects
ADVERSE health care events; EPITHELIAL cell tumors; IMMUNE checkpoint inhibitors; INFECTIOUS arthritis; JOINT diseases; RISK assessment; CANCER patients; POLYMYALGIA rheumatica; RHEUMATISM; MYOSITIS; IMMUNOTHERAPY; DISEASE risk factors
- Publication
Oncologist, 2022, Vol 27, Issue 4, pe353
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyac026